製品の概要

  • 製品名Anti-MAFA antibody
    MafA 一次抗体 製品一覧
  • 製品の詳細
    Rabbit polyclonal to MAFA
  • アプリケーション適用あり: ICC/IF, WBmore details
  • 種交差性
    交差種: Human
    交差が予測される動物種: Mouse, Rat
  • 免疫原

    Synthetic peptide corresponding to a region within N terminal sequence amino acids 71-120 of Human MAFA (NP_963883).

  • ポジティブ・コントロール
    • Human fetal thymus lysate IF/ICC: MCF7 cell line.

製品の特性

アプリケーション

Our Abpromise guarantee covers the use of ab98859 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
ICC/IF Use a concentration of 5 µg/ml.
WB Use a concentration of 1 µg/ml. Predicted molecular weight: 37 kDa. Good results were obtained when blocked with 5% non-fat dry milk in 0.05% PBS-T.

ターゲット情報

  • 機能Acts as a transcriptional factor. Specifically binds the insulin enhancer element RIPE3b and activates insulin gene expression. Cooperates synergistically with NEUROD1 and PDX1. Phosphorylation by GSK3 increases its transcriptional activity and is required for its oncogenic activity. Involved either as an oncogene or as a tumor suppressor, depending on the cell context.
  • 配列類似性Belongs to the bZIP family. Maf subfamily.
    Contains 1 bZIP domain.
  • 翻訳後修飾Ubiquitinated, leading to its degradation by the proteasome.
    Ser-14 and Ser-65 appear to be the major phosphorylation sites. Phosphorylated by MAPK13 on serine and threonine residues (Probable). Phosphorylation by GSK3 requires prior phosphorylation of Ser-65 by another kinase. Phosphorylation proceeds then from Ser-61 to Thr-57, Thr-53 and Ser-49. GSK3-mediated phosphorylation increases its transcriptional activity through the recruitment of the coactivator PCAF, is required for its transforming activity and leads to its degradation through an ubiquitin/proteasome-dependent pathway.
  • 細胞内局在Nucleus. Detected in nuclei of pancreas islet beta cells.
  • Information by UniProt
  • 参照データベース
  • 別名
    • HMafA antibody
    • Mafa antibody
    • MAFA_HUMAN antibody
    • Pancreatic beta cell specific transcriptional activator antibody
    • Pancreatic beta-cell-specific transcriptional activator antibody
    • RIPE3b1 antibody
    • Transcription factor MafA antibody
    • Transcription factor RIPE3b1 antibody
    • v maf musculoaponeurotic fibrosarcoma oncogene homolog A (avian) antibody
    • v maf musculoaponeurotic fibrosarcoma oncogene homolog A antibody
    • V-maf musculoaponeurotic fibrosarcoma oncogene homolog A antibody
    see all

Anti-MAFA antibody 画像

  • ICC/IF image of ab98859 stained MCF7 cells. The cells were 100% Methanol fixed (5 min) and then incubated in 1%BSA / 10% normal Goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab98859, 5µg/ml) overnight at +4°C. The secondary antibody (green) was ab96899, DyLight® 488 Goat anti-Rabbit IgG (H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

  • Anti-MAFA antibody (ab98859) at 1 µg/ml (in 1 X PBS, pH 7.4 containing 5% dry milk) + Human fetal thymus lysate at 10 µg
    Developed using the ECL technique

    Predicted band size : 37 kDa
    12% gel

Anti-MAFA antibody (ab98859) 使用論文

ab98859 has not yet been referenced specifically in any publications.

Product Wall

Application Immunohistochemistry (PFA perfusion fixed frozen sections)
Blocking step Serum as blocking agent for 30 minute(s) · Concentration: 10% · Temperature: 20°C
Antigen retrieval step None
Sample Mouse Tissue sections (e12.5 mouse embryonic spinal cord)
Specification e12.5 mouse embryonic spinal cord
Permeabilization Yes - 0.1%Triton X-100
Fixative Paraformaldehyde
Username

Dr. Frederic Clotman

Verified customer

投稿 Jul 21 2014

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"